Cellipont Bioservices' Texas Facility Has Supported Six Client Projects Expected to Reach IND Submission in 2026

Trial StartPositive

AI Analysis

Summary

Cellipont Bioservices announced that its Texas facility has supported six client projects expected to reach IND submission in 2026. The announcement highlights the CDMO's capacity in cell therapy development and manufacturing services.

Importance:3/10

Sentiment:

0.30

cell therapyCDMOIND submissionTexas facilitymanufacturing

Read the original article

Published by PR Newswire Clinical Trials on September 3, 2026 2:28 PM

Read Original